Objective: To examine the effects of lecithin on serum lipoprotein, plasma ®brinogen and macro molecular protein complex (MPC) levels. Subjects and study design: Twenty free living hyperlipidaemic men participated in this double-blind study which controlled for possible indirect effects. The subjects were randomly assigned to one of three treatments: frozen yoghurt or frozen yoghurt with 20 g soya bean lecithin or frozen yoghurt with 17 g sun¯ower oil.
Introduction
Lecithin (phosphatidylcholine) is choline containing phospholipids which also includes glycerol esteri®ed with fatty acids (Gurr, 1993) . Lecithin has emulsifying properties and is an essential component of biomembranes and lipoproteins. Liver, egg yolk and soya beans are especially rich sources of lecithin (Mahan & Arlin, 1992) . Most of the commercial lecithin brands claim hypocholesterolaemic effects and are therefore prescribed by health practitioners for treatment of increased lipoprotein levels. The assumption that lecithin lowers lipoprotein levels is based on evidence from studies done from the 1940s to the early 1980s (Davies & Murdoch, 1959; Morrison, 1958; Saba et al, 1978; Steiner & Domanski 1944; Tompkins & Parkin, 1980) and most of these studies were poorly designed and showed controversial results. Some of the major design errors were the following: Firstly, small, heterogenic study groups were used, for example a study group of eight consisting of men and women with different types of dyslipidaemia including familial hypercholesterolaemia, hypercholesterolaemia, combined hyperlipidaemia and normal lipidaemia (Childs et al, 1981; Davies & Murdoch, 1959; Greten et al, 1980; Saba et al, 1978; Tompkins & Parkin, 1980) . Secondly, most studies lacked an appropriate control group (Cobb et al, 1980; Davies & Murdoch, 1959; Saba et al, 1978; Ter Welle et al, 1974; Tompkins & Parkin, 1980) . Knuiman et al (1989) highlighted four out of twenty four studies that attempted to control for the fatty acid component of lecithin namely, the studies done by Greten et al (1980) , Childs et al (1981) , Prack et al (1983) and Kesaniemi & Grundy (1986) . These studies could, however, not demonstrate any independent effects of lecithin on serum cholesterol. Thirdly, in the studies where control groups were included with cross-over designs, no or too short washout periods existed between control (soya bean oil or saf¯ower oil) and lecithin treatments (Greten et al, 1980; Kesaniemi & Grundy, 1986) . Fourthly, control and lecithin treatment periods were not randomized with no reference group either. For example, all the subjects will follow the control diet ®rst and then switch to the experimental diet or vice versa (Childs et al, 1981; Greten et al, 1980; Kesaniemi & Grundy, 1986; Ter Welle et al, 1974) .
Plasma ®brinogen is an independent risk factor for coronary heart disease and is positively associated with total cholesterol, low density lipoprotein cholesterol, triglycerides and negatively associated with high density lipoprotein cholesterol (Ernst & Resch, 1993) . A macro molecular protein complex (MPC) which form complexes with the ®brin network in blood clots, increasing clot mass and decreasing clot ®brinolysis was described. It is hypothesized that high MPC levels increase thrombotic risk (Lipinski et al, 1995) . Veldman (1996) showed that MPC levels can be manipulated through dietary intervention in a study where pectin, a soluble dietary ®bre component, decreased MPC levels signi®cantly. No information on the effects of lecithin on plasma ®brinogen or MPC levels could be found.
In this study the effect of a new, pure (96% phospholipids) soya bean lecithin product on serum lipoproteins, plasma ®brinogen and MPC levels were investigated by using a double-blind study design in which possible indirect effects were controlled for.
Methods

Subjects
The study was approved by the Ethics Committee of the Potchefstroom University for Christian Higher Education and an informed consent form was signed by each participant. Twenty-one hyperlipidaemic men with a mean ( AE standard deviation) age of 48.25 AE 9.75 y who regularly attended the Lipid Clinic at the Potchefstroom University, participated in this study.
The study was done under free living conditions. The exclusion criteria were: smoking, baseline serum total cholesterol (TC) levels`5.2 mmolaL, baseline serum triglyceride (TG) levels b 5 mmolaL, familial hypercholesterolaemia, baseline fasting blood glucose b 6.7 mmol/ L, body mass index (BMI) b 30 kg/m 2 , and use of lipid lowering drugs.
Study design
At entering the Lipid Clinic all subjects were prescribed a high-®bre, low-fat diet. Compliance to the diet varied. However, all but two subjects were stabilized on their individual adapted diets. Subjects were paired off into three groups of seven subjects each according to their baseline serum TC levels, age and body mass index (BMI). The groups were then randomly assigned to one of three treatments, namely: (1) 175 gad of frozen yoghurt; (2) 175 gad of frozen yoghurt with 20 g soya bean lecithin; and (3) 175 gad of frozen yoghurt with 17 g sun¯ower oil.
The compositions of the three treatments are summarized in Table 1 . By mixing the sun¯ower oil and soya bean lecithin into the yoghurt, blindness was ensured. Skim milk yoghurt was chosen as the`vehicle' for the lecithin and sun¯ower oil because it is compatible with the low-fat diet. Yoghurt alone was given to one group to control for possible effects due to the yoghurt`vehicle', as well as other environmental in¯uences. Sun¯ower oil was included in the yoghurt of another group to control for the increased energy and linoleic acid intake from lecithin, because an intake of 20 g of SternpurPM lecithin provides 622 kJ (148 kcal) and contains 59% linoleic acid (Stern typisch Lecithin & Soja, Hamburg, Germany). After two baseline fasting blood samples (one week apart) and anthropometric measurements (height and weight) were obtained, the subjects started with the treatment. The means of the two baseline values were calculated. Fasting blood samples and anthropometric measurements were then taken after two and four weeks of treatment, BMI (kgam 2 ) was calculated. The subjects were asked to maintain their usual diet, alcohol consumption and physical activity. One of the subjects in the lecithin group was excluded from the analysis, because he did not maintain his usual lifestyle. He went on vacation and gained 7 kg.
Blood samples
The subjects were required to fast overnight (12 h). Venous blood samples were collected using a 21-gauge scalp vein infusion set. All samples were drawn with minimal stasis and between 07:00 and 10:00 to avoid effects of diurnal variation. EDTA blood was used for the analysis of haematocrit and haemoglobin. Clotted, citrated and EDTA blood was centrifuged for 15 min at 2000 g to yield serum for lipoprotein, plasma for haemostatic and plasma for fatty acid assays, respectively. Serum and plasma were divided into aliquots and frozen at 7 72 C within 30 min for later analysis.
Experimental methods
To monitor compliance, the fatty acid composition of total plasma lipids was determined with chloroformamethanol extractions as described by Smuts et al (1992) (coef®cient of variance (CV) 4%). Total cholesterol (TC) concentrations were determined enzymatically with the Technicon Omnipak-method ((SM-4-0139a86), Bayer, Puteaux Cedex). Low density lipoprotein cholesterol (LDL) was determined with the CHOD-Iodide method (Merck, Darmstadt, Germany). LDL was precipitated by heparin at its iso-electric point (pH 5.12). After centrifugation, the high density lipoprotein cholesterol (HDL) and the very low density lipoprotein cholesterol (VLDL) remained in the supernatant and were determined with enzymatic methods. The LDL concentration was then calculated according to 
Statistical analysis
Because a normal distribution of data could not be assumed, signi®cant differences within groups were determined with the Wilcoxon matched pairs test and between groups with the Mann±Whitney U-test. The computer software package Statistica 1 was used for these analyses. 95% Con®dence intervals (CI) were calculated (Conover, 1971) . All data are presented as median (95% CI). A P-value of less than or equal to 0.05 was regarded as being statistically signi®cant.
Results
The median (95% CI) levels of the variables during yoghurt, lecithin and sun¯ower oil treatments are summarized in Tables 2±5.  Table 2 indicates that plasma linoleic acid (C18:2) levels increased signi®cantly with both lecithin and sun¯ower oil treatments and were also signi®cantly higher after two weeks of treatment, compared to the yoghurt group. Plasma palmitic (C16:0) and palmitoleic acid (C16:1) levels increased signi®cantly in the yoghurt group. After four weeks of treatment the median palmitic acid level was signi®cantly higher compared to the lecithin and sun¯ower oil groups. Plasma stearic acid (C18:0) and oleic acid (C18:1) levels did not change with any of the treatments while plasma gamma-linolenic acid (C18:3, n-6) levels decreased signi®cantly with sun¯ower oil treatment and alpha-linolenic acid (C18:3, n-3) levels increased with lecithin treatment.
Weight and BMI was not affected in the yoghurt and lecithin groups, but increased signi®cantly with sun¯ower oil treatment. Haemoglobin levels tended to decrease in the lecithin and sun¯ower oil groups and the decrease was signi®cant in the yoghurt group. These small decreases were, probably, not of any clinical signi®cance, because reference values for haemoglobin in men are 8.68± 11.16 mmolaL (Lee & Nieman, 1993) . Haematocrit levels did not change with any of the treatments (Table 3) .
As shown in Table 4 , lecithin therapy had no effect on serum TC, TG, HDL, LDL, LDLaHDL or apoA levels. Serum apoB and Lp(a) levels increased signi®cantly after two weeks of lecithin treatment, but these levels returned to baseline levels after four weeks of treatment. Serum TC levels increased signi®cantly in the group who received sun¯ower oil. HDL-C levels decreased and LDLaHDL ratio increased signi®cantly in the yoghurt group, but these changes were probably not of any clinical signi®cance.
Plasma ®brinogen and MPC levels were not effected by yoghurt or lecithin treatments, but MPC-levels were signi®cantly reduced by sun¯ower oil treatment (Table 5) .
Discussion
The signi®cant increases in plasma linoleic acid levels with both lecithin and sun¯ower oil treatments indicate good compliance to the treatments. Because the lecithin product also contains 7% waw of alpha-linolenic acid (Stern Lecithin & Soja GmbH & Co Kg, Hamburg, Germany) the signi®cant increase in plasma alpha-linolenic acid levels may also be indicative of good compliance to the Lecithin effects on serum lipoproteins, plasma ®brinogen and MPC W Oosthuizen et al lecithin treatment. Plasma palmitic and palmitoleic acid levels increased signi®cantly in the control group. These more saturated fatty acids (SFA) might have been synthesized in the body from an increased intake of carbohydrate (Lands, 1995) , because it has been indicated that the SFA composition in the plasma is not a good indicator of dietary intake of SFA (Simon et al, 1995) . The signi®cant decrease in gamma-linolenic acid levels with sun¯ower oil treatment is probably of no clinical signi®cance since the changes in the yoghurt and lecithin groups were even greater although not signi®cant. The salient observations of this study on free living hyperlipidaemic men were that lecithin had no effect on the measured risk factors and markers for coronary heart disease but that the sun¯ower oil resulted in increase in body weight, serum TC and reduced plasma MPC levels. The increased serum TC levels may probably be explained by the increase in body weight in these subjects (Newman et al, 1990) .
Results from clinical trials of lecithin have reported total cholesterol and LDL lowering effects (Davies & Murdoch, 1959; Morrison, 1958; Saba et al, 1978; Steiner & Domanski, 1944; Tompkins & Parkin, 1980) while other studies showed no signi®cant effects (Childs et al, 1981; Cobb et al, 1980; Greten et al, 1980; Kesaniemi & Grundy, 1986; Ter Welle et al, 1974) . A decreasing effect of lecithin on TG-levels (Cobb et al, 1980; Saba et al, 1978; Tompkins & Parkin, 1980) and in some studies no effect (Childs et al, 1981; Greten et al, 1980; Kesaniemi & Grundy, 1986; Ter Welle et al, 1974 ) have been reported. Some studies reported no effect of lecithin on HDL levels (Greten et al, 1980; Kesaniemi & Grundy, 1986; Prack et al, 1983) , while Childs et al (1981) reported an increasing effect on HDL, independent of its polyunsaturated fatty acid moiety. As discussed in the introduction most of these studies were poorly designed and are not comparable to the present study because of the different study designs, different amounts of lecithin used, ranging from 0.7±54 gad (Knuiman et al, 1989) , and different concentrations of phospholipids in lecithin products, ranging from 29% (Childs et al, 1981) to 96% in the present study.
It has been demonstrated in humans that intake of lecithin (Kesaniemi & Grundy, 1986 ) and infusion of lecithin intraduodenally (Beil & Grundy, 1980) , decreases the absorption of cholesterol in the small intestine. Kesaniemi & Grundy (1986) suggested that if lecithin is given in multiple doses throughout the day, the inhibition of cholesterol absorption might be higher and that the amount of dietary cholesterol may also have an effect on the results. This may, in part, explain why lecithin did not lower TC levels in this particular study, because these subjects followed a low cholesterol diet. Other studies in which subjects followed a low cholesterol baseline diet could also not demonstrate TC lowering with lecithin (Greten et al, 1980; Kesaniemi & Grundy, 1986) .
In this study lecithin treatment had no effect on plasma ®brinogen or MPC levels, but sun¯ower oil treatment decreased MPC levels signi®cantly that may probably decrease thrombotic risk (Lipinski et al, 1995) . This possible bene®cial effect of sun¯ower oil on MPC needs to be further investigated.
Conclusion
Lecithin treatment had no independent effects on serum lipoproteins, plasma ®brinogen or MPC levels in free living hyperlipidaemic men in a double-blind study which controlled for possible indirect effects.
